What are the pharmacotherapy options for treating prediabetes?

Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates

(2013) R. A. DeFronzo et al.   DIABETES

Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release

(2013) W. Timothy Garvey et al.   DIABETES CARE

In Vivo Actions of Peroxisome Proliferator-Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion

(2013) R. Eldor et al.   DIABETES CARE

Observational follow-up of the PROactive study: a 6-year update

(2013) E. Erdmann et al.   DIABETES OBESITY & METABOLISM

Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans

(2012) J. J. Meier et al.   DIABETOLOGIA

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose

(2011) Mustafa Kanat et al.   ACTA DIABETOLOGICA

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

(2011) W Timothy Garvey et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

The Relationship Between  -Cell Function and Glycated Hemoglobin: Results from the Veterans Administration Genetic Epidemiology Study

(2011) M. Kanat et al.   DIABETES CARE

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study

(2011) J. D. Lewis et al.   DIABETES CARE

Effects of Exenatide on Measures of  -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

(2011) M. C. Bunck et al.   DIABETES CARE

Predictors of lifestyle intervention outcome and dropout: the SLIM study

(2011) C Roumen et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

(2011) Daniel J. Drucker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Pathophysiology of Prediabetes

(2011) Ele Ferrannini et al.   MEDICAL CLINICS OF NORTH AMERICA

Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance

(2011) Ralph A. DeFronzo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

(2010) J. Rosenstock et al.   DIABETES CARE

Lifestyle Intervention for Prevention of Type 2 Diabetes in Primary Health Care: One-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D)

(2010) T. Saaristo et al.   DIABETES CARE

Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose

(2010) Leigh Perreault et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes

(2010) Muhammad A. Abdul-Ghani et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

(2010) M. A. Nauck et al.   DIABETOLOGIA

Pathogenesis of Insulin Resistance in Skeletal Muscle

(2010) Muhammad A. Abdul-Ghani et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes

(2010) Dori Bilik et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis

(2010) Richard Kahn et al.   LANCET

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study

(2010) Bernard Zinman et al.   LANCET

Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy

(2010) Mary Parks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice

(2009) Ryuichi Moriya et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type

(2009) Yoshinori Miyazaki et al.   Cardiovascular Diabetology

Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice

(2009) J. A. Koehler et al.   DIABETES

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Secondary Failure of Metformin Monotherapy in Clinical Practice

(2009) J. B. Brown et al.   DIABETES CARE

Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabeticdb/dbmice

(2009) Y. Moritoh et al.   DIABETES OBESITY & METABOLISM

Regulation of insulin secretion: a matter of phase control and amplitude modulation

(2009) J. C. Henquin   DIABETOLOGIA

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance

(2009) Ryuzo Kawamori et al.   LANCET

A randomized lifestyle intervention with 5-year follow-up in subjects with impaired glucose tolerance: Pronounced short-term impact but long-term adherence problems

(2009) Bernt Lindahl et al.   SCANDINAVIAN JOURNAL OF PUBLIC HEALTH

Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism

(2009) E. Slack et al.   SCIENCE

The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance

(2008) Muhammad A. Abdul-Ghani et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA

First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes

(2008) E M Venditti et al.   INTERNATIONAL JOURNAL OF OBESITY

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

(2008) Guangwei Li et al.   LANCET

End of the line for cannabinoid receptor 1 as an anti-obesity target?

(2008) Dan Jones   NATURE REVIEWS DRUG DISCOVERY

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE